Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Allogene Therapeutics, Inc.
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
May 6, 2026
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
May 6, 2026
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
May 6, 2026
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
May 6, 2026
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
April 29, 2026
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
March 13, 2026
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
March 9, 2026
←
Previous Page
1
2